Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021

Wolf, S. (2021): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer. Update September 2021. Oncology Fact Sheet Nr. 51.

[thumbnail of Oncology Fact Sheet Nr.51_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
124kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 400-560 Intestines WI Digestive system > WI 600-650 Anus. Rectum
Language:	English
Series Name:	Oncology Fact Sheet Nr. 51
Deposited on:	28 Jun 2021 13:56
Last Modified:	15 Sep 2021 14:28

Repository Staff Only: item control page